Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study

M. Azadi, D. M. Bishai, D. W. Dowdy, L. H. Moulton, S. Cavalcante, V. Saraceni, A. G. Pacheco, S. Cohn, R. E. Chaisson, B. Durovni, J. E. Golub

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


DESIGN : We used decision analysis, populated by data from a cluster-randomized trial, to project the costs (in 2010 USD) and effectiveness (in disability-adjusted life years [DALYs] averted) of training health care workers to implement the tuberculin skin test (TST), followed by IPT for TST-positive patients with no evidence of active TB. This intervention was compared to a baseline of usual care. We used time horizons of 1 year for the intervention and 20 years for disease outcomes, with all future DALYs and medical costs discounted at 3% per year.

RESULTS : Providing this intervention to 100 people would avert 1.14 discounted DALYs (1.57 undiscounted DALYs). The median estimated incremental cost-effectiveness ratio was $2273 (IQR $1779-$3135) per DALY averted, less than Brazil's 2010 per capita gross domestic product (GDP) of $11 700. Results were most sensitive to the cost of providing the training.

CONCLUSION: Training health care workers to screen HIV-infected adults with TST and provide IPT to those with latent tuberculous infection can be considered costeffective relative to the Brazilian GDP per capita.

OBJECTIVE : To estimate the incremental cost-effectiveness of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) among human immunodeficiency virus (HIV) infected adults in Rio de Janeiro, Brazil.

Original languageEnglish (US)
Pages (from-to)1443-1448
Number of pages6
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number12
StatePublished - Dec 1 2014


  • Brazil
  • Economic analysis
  • IPT
  • Skin tests
  • TB-HIV co-infection

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases


Dive into the research topics of 'Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study'. Together they form a unique fingerprint.

Cite this